ConductScience.org, home

Paper39748842

The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.

Bakker A and 3 others. Alzheimers Dement (N Y), 2024. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease. Papers, record 39748842. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39748842

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.
PubMed
Journal
Alzheimers Dement (N Y)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
1.87, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bakker AArnoldhttps://orcid.org/0000-0003-0417-641X
2Rani NNisha
3Mohs RRichard
4Gallagher MMichela

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 AG066507NIA NIH HHSUnited StatesP30AG066507PubMedNIH RePORTER
R01 AG048349NIA NIH HHSUnited StatesR01AG048349PubMedNIH RePORTER
R01 AG061091NIA NIH HHSUnited StatesR01AG061091PubMedNIH RePORTER
R56 AG055416NIA NIH HHSUnited StatesR56AG055416PubMedNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in40642320Correction to "The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease".https://conductscience.org/library/papers/40642320

Source PubMed

Download CSV of comments and corrections

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125181316Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment.Hum Brain Mapp2015https://conductscience.org/library/papers/25181316PubMed
238356475The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.Alzheimers Dement (N Y)2024https://conductscience.org/library/papers/38356475PubMed
322869752Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22869752PubMed
420032967Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.Neuropsychopharmacology2010https://conductscience.org/library/papers/20032967PubMed
536251300Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.JAMA Neurol2022https://conductscience.org/library/papers/36251300PubMed
630552075Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment.Neuroimage Clin2019https://conductscience.org/library/papers/30552075PubMed
713677801Neuroimaging in Alzheimer disease: an evidence-based review.Neuroimaging Clin N Am2003https://conductscience.org/library/papers/13677801PubMed
839748842The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.Alzheimers Dement (N Y)2024https://conductscience.org/library/papers/39748842PubMed
922578498Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.Neuron2012https://conductscience.org/library/papers/22578498PubMed
1016087905Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD.Neurology2005https://conductscience.org/library/papers/16087905PubMed
1128269019ITK-SNAP: An interactive tool for semi-automatic segmentation of multi-modality biomedical images.Annu Int Conf IEEE Eng Med Biol Soc2016https://conductscience.org/library/papers/28269019PubMed
1222732662Multi-Atlas Segmentation with Joint Label Fusion.IEEE Trans Pattern Anal Mach Intell2013https://conductscience.org/library/papers/22732662PubMed
1310762153Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.Ann Neurol2000https://conductscience.org/library/papers/10762153PubMed
1428971142Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry.Alzheimers Dement (Amst)2017https://conductscience.org/library/papers/28971142PubMed
1510023955MRI of entorhinal cortex in mild Alzheimer's disease.Lancet1999https://conductscience.org/library/papers/10023955PubMed
1621696834Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.Trends Neurosci2011https://conductscience.org/library/papers/21696834PubMed
1733720637Donanemab in Early Alzheimer's Disease.N Engl J Med2021https://conductscience.org/library/papers/33720637PubMed
1821514249
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement2011https://conductscience.org/library/papers/21514249PubMed
197566337Staging of Alzheimer's disease-related neurofibrillary changes.Neurobiol Aging1995https://conductscience.org/library/papers/7566337PubMed
2020566298Non-local MRI upsampling.Med Image Anal2010https://conductscience.org/library/papers/20566298PubMed

See all 35 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42890321Comparative efficacy of non-pharmacological interventions for amnestic mild cognitive impairment: a network meta-analysis.Front Aging Neurosci2026https://conductscience.org/library/papers/42890321PubMed
42564239The impact of long-term antiseizure treatment on cognitive decline in late-onset epileptic prodromal Alzheimer's disease: an exploratory study.Front Aging Neurosci2026https://conductscience.org/library/papers/42564239PubMed
42453713Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment.AIMS Neurosci2026https://conductscience.org/library/papers/42453713PubMed
42344858Introducing the SAGE study: a multimodal protocol for testing a GABAergic mechanism of age-related episodic memory impairment across the sexes.BMJ Neurol Open2026https://conductscience.org/library/papers/42344858PubMed
42337959Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non-pharmacological strategies.Alzheimers Dement2026https://conductscience.org/library/papers/42337959PubMed
41840186Maintaining and regaining episodic memory in Alzheimer disease: a circuit-based perspective.Nat Rev Neurol2026https://conductscience.org/library/papers/41840186PubMed
41599368Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease.Molecules2026https://conductscience.org/library/papers/41599368PubMed
41554957Excitation-inhibition homeostasis in Alzheimer's disease: a selective multiscale review of mechanisms, sex differences, and therapeutic opportunities.Neuropsychopharmacology2026https://conductscience.org/library/papers/41554957PubMed
40993829Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer's disease: associations with Aβ, tau, synaptic proteins and APOE ε4.Transl Neurodegener2025https://conductscience.org/library/papers/40993829PubMed
40608289Effect of levetiracetam on cognition in patients with cognitive decline: A systematic review and meta-analysis of randomized controlled trials.Epilepsia Open2025https://conductscience.org/library/papers/40608289PubMed
40595720Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease.Nat Commun2025https://conductscience.org/library/papers/40595720PubMed
39748842The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non-carriers with mild cognitive impairment due to Alzheimer's disease.Alzheimers Dement (N Y)2024https://conductscience.org/library/papers/39748842PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39748842

GET https://conductscience.org/api/papers/v1/39748842/references?page=2